FeesSafety
Pluang+

Seanergy Maritime posts record Q2 net income of $26.2M, expands fleet renewal with $591M investment.

Company Fundamentals
30 Jul 2026
GlobeNewsWire
View Source
Bullish
Seanergy Maritime posts record Q2 net income of $26.2M, expands fleet renewal with $591M investment.

Seanergy Maritime Holdings Corp. reported a record net income of $26.2 million for Q2 2026, a significant increase from $2.9 million in Q2 2025, driven by strong fleet performance and higher charter rates. The company declared its 19th consecutive quarterly dividend of $0.35 per share and expanded its fleet renewal program to $591 million, adding eight modern Capesize and Newcastlemax vessels. Seanergy also completed a €100 million unsecured bond offering to support its growth and secured long-term charters for new vessels, positioning itself for continued strong earnings and shareholder returns.

More News

Canada's Royal Canadian Legion launches 2026 Poppy Campaign with new contactless donations and a commemorative mural.

Canada's Royal Canadian Legion launches 2026 Poppy Campaign with new contactless donations and a commemorative mural.

The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...

Others
Bullish
1 hour ago
XBiotech appoints Jan-Paul Simard as Co-CEO alongside Sushma Shivaswamy to strengthen leadership.

XBiotech appoints Jan-Paul Simard as Co-CEO alongside Sushma Shivaswamy to strengthen leadership.

XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...

Market News
Bullish
2 hours ago
XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs to lead antibody therapy development.

XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs to lead antibody therapy development.

XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...

Market News
Bullish
2 hours ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
3 hours ago
Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App